About Merrimack Pharmaceuticals (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-1.47
Forward P/E Ratio-1.78
Sales & Book Value
Annual Sales$144.27 million
Price / Sales0.77
Price / CashN/A
Book Value$7.22 per share
Price / Book1.15
EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Return on Equity-773.68%
Return on Assets-50.11%
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals (NASDAQ:MACK) announced its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.30) by $0.70. The biopharmaceutical company had revenue of $33.70 million for the quarter, compared to the consensus estimate of $33.35 million. Merrimack Pharmaceuticals's revenue was up 58.3% on a year-over-year basis. During the same period in the prior year, the business earned ($3.30) EPS. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
2 Wall Street analysts have issued 1 year target prices for Merrimack Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Sinovac Biotech (SVA), Innate Pharma (IPHYF), Depomed (DEPO), ProMetic Life Sciences (PFSCF), MediciNova (MNOV), Concert Pharmaceuticals (CNCE), Prothena (PRTA), Synergy Pharmaceuticals (SGYP), Sienna Biopharmaceuticals (SNNA), Cara Therapeutics (CARA), Syros Pharmaceuticals (SYRS), Cytokinetics (CYTK), Kala Pharmaceuticals (KALA), GTX (GTXI) and Albireo (ALBO).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Ulrik B. Nielsen, Co-Founder & Director (Age 46)
- Dr. Richard Peters, CEO, Pres & Director (Age 55)
- Dr. Anthony J. Sinskey, Co-Founder and Scientific Advisor (Age 78)
- Dr. Gavin MacBeath Ph.D., Founder
- Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
Media coverage about MACK stock has trended positive this week, Accern Sentiment reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a coverage optimism score of 0.27 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $8.33.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $112.88 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Merrimack Pharmaceuticals (NASDAQ:MACK) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.53%
Institutional Ownership Percentage: 54.16%
Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/15/2017||Ulrik B Nielsen||Director||Sell||7,896||$14.23||$112,360.08||22,781|| |
|9/14/2017||Ulrik B Nielsen||Director||Sell||100||$14.20||$1,420.00||22,781|| |
|9/13/2017||Ulrik B Nielsen||Director||Sell||21,556||$14.40||$310,406.40||37,437|| |
|9/11/2017||Ulrik B Nielsen||Director||Sell||14,756||$14.46||$213,371.76||37,437|| |
|5/12/2017||Daryl C Drummond||Insider||Sell||4,097||$3.72||$15,240.84|| |
|7/25/2016||Birgit M Schoeberl||Insider||Sell||50,000||$5.50||$275,000.00||115,657|| |
|3/17/2016||Michael E Porter||Director||Buy||5,000||$7.20||$36,000.00||754,448|| |
|3/15/2016||Michael E Porter||Director||Buy||5,000||$7.65||$38,250.00||749,448|| |
|3/8/2016||Michael E Porter||Director||Buy||10,000||$7.09||$70,900.00||744,448|| |
|3/3/2016||Michael E Porter||Director||Buy||15,000||$6.39||$95,850.00||724,448|| |
|3/1/2016||Michael E Porter||Director||Buy||20,000||$6.11||$122,200.00||709,448|| |
|2/29/2016||Vivian S Lee||Director||Buy||35,000||$5.50||$192,500.00||65,000|| |
|2/29/2016||William M Mcclements||Insider||Buy||2,000||$5.72||$11,440.00||14,072|| |
|1/5/2016||Edward J. Stewart||insider||Sell||4,000||$8.00||$32,000.00||21,385|| |
|12/1/2015||Edward J. Stewart||insider||Sell||5,000||$9.33||$46,650.00||21,385|| |
|11/2/2015||Edward J. Stewart||insider||Sell||6,000||$9.42||$56,520.00||21,385|| |
|10/16/2015||Edward J. Stewart||insider||Sell||1,000||$10.00||$10,000.00||21,385|| |
|10/2/2015||Edward J. Stewart||insider||Sell||5,000||$8.20||$41,000.00||21,385|| |
|9/1/2015||Edward J. Stewart||insider||Sell||6,000||$9.88||$59,280.00||21,385|| |
|8/21/2015||Michael E Porter||Director||Buy||5,000||$9.76||$48,800.00||699,448|| |
|8/17/2015||Edward J. Stewart||insider||Sell||6,000||$10.49||$62,940.00||21,385|| |
|8/14/2015||Michael E Porter||Director||Buy||13,000||$10.54||$137,020.00|| |
|7/20/2015||Ulrik B Nielsen||Director||Sell||20,000||$10.71||$214,200.00|| |
|7/15/2015||Edward J Stewart||Insider||Sell||6,000||$11.84||$71,040.00|| |
|7/15/2015||William A Sullivan||CFO||Sell||15,000||$11.85||$177,750.00|| |
|6/19/2015||Ulrik B Nielsen||Director||Sell||40,000||$12.02||$480,800.00|| |
|6/18/2015||Edward J Stewart||Insider||Sell||2,000||$12.00||$24,000.00|| |
|6/15/2015||Edward J Stewart||Insider||Sell||6,000||$10.67||$64,020.00|| |
|6/15/2015||William A Sullivan||CFO||Sell||15,000||$10.65||$159,750.00|| |
|5/19/2015||Ulrik B Nielsen||Director||Sell||40,000||$13.04||$521,600.00|| |
|5/13/2015||Michael E Porter||Director||Buy||8,284||$11.79||$97,668.36|| |
|4/20/2015||Ulrik B Nielsen||Director||Sell||40,000||$12.88||$515,200.00|| |
|4/15/2015||Edward J Stewart||SVP||Sell||8,000||$12.79||$102,320.00|| |
|4/15/2015||William A Sullivan||CFO||Sell||15,000||$12.87||$193,050.00|| |
|4/13/2015||Gordon J Fehr||Director||Sell||20,000||$13.00||$260,000.00|| |
|3/24/2015||Robert J Mulroy||CEO||Sell||114,368||$11.71||$1,339,249.28|| |
|3/23/2015||Robert J Mulroy||CEO||Sell||10,400||$11.69||$121,576.00|| |
|3/20/2015||Michael E Porter||Director||Buy||5,000||$11.77||$58,850.00|| |
|3/19/2015||Ulrik B Nielsen||Director||Sell||40,000||$11.97||$478,800.00|| |
|3/19/2015||William A Sullivan||CFO||Sell||15,000||$11.97||$179,550.00|| |
|3/17/2015||Birgit M Schoeberl||Insider||Sell||42,234||$12.00||$506,808.00|| |
|3/17/2015||Edward J Stewart||SVP||Sell||8,000||$11.95||$95,600.00|| |
|3/17/2015||Michael E Porter||Director||Buy||1,190||$11.77||$14,006.30|| |
|3/16/2015||Birgit M Schoeberl||Insider||Sell||20,897||$12.00||$250,764.00|| |
|3/16/2015||Edward J Stewart||SVP||Sell||6,000||$11.93||$71,580.00|| |
|3/11/2015||Michael E Porter||Director||Buy||5,000||$11.33||$56,650.00|| |
|3/2/2015||Michael E Porter||Director||Buy||5,000||$10.93||$54,650.00|| |
|2/23/2015||Ulrik B Nielsen||Director||Sell||20,000||$10.91||$218,200.00|| |
|2/20/2015||Robert J Mulroy||CEO||Sell||150,000||$10.94||$1,641,000.00|| |
|1/15/2015||Edward J Stewart||SVP||Sell||6,000||$11.19||$67,140.00|| |
|12/24/2014||William A Sullivan||CFO||Sell||15,000||$10.70||$160,500.00|| |
|12/23/2014||Vivian S Lee||Director||Buy||20,000||$10.23||$204,600.00|| |
|12/18/2014||Anthony J Sinskey||Director||Sell||20,000||$10.31||$206,200.00|| |
|12/15/2014||Edward J Stewart||SVP||Sell||6,000||$10.63||$63,780.00|| |
|12/8/2014||Robert J Mulroy||CEO||Sell||200,000||$9.84||$1,968,000.00|| |
|12/2/2014||Michael E Porter||Director||Buy||8,000||$8.71||$69,680.00|| |
|11/21/2014||Michael E Porter||Director||Buy||11,909||$8.87||$105,632.83|| |
|11/18/2014||Edward J Stewart||SVP||Sell||5,000||$8.55||$42,750.00|| |
|11/14/2014||Michael E Porter||Director||Buy||5,000||$8.29||$41,450.00|| |
|11/13/2014||Gary L Crocker||Director||Buy||14,390||$8.47||$121,883.30|| |
|11/12/2014||Michael E Porter||Director||Buy||40,000||$8.37||$334,800.00|| |
|10/23/2014||Edward J Stewart||SVP||Sell||3,000||$9.05||$27,150.00|| |
|9/30/2014||William A Sullivan||CFO||Sell||105,282||$8.61||$906,478.02|| |
|9/29/2014||William A Sullivan||CFO||Sell||64,404||$8.40||$540,993.60|| |
|9/24/2014||Edward J Stewart||SVP||Sell||12,000||$8.22||$98,640.00|| |
|6/23/2014||Gary L Crocker||Director||Buy||36,000||$6.84||$246,240.00|| |
|5/20/2014||Gary Crocker||Director||Buy||4,000||$6.69||$26,760.00||2,808,571|| |
|5/19/2014||Gary Crocker||Director||Buy||9,400||$6.68||$62,792.00||2,804,571|| |
|5/16/2014||Michael Porter||Director||Buy||15,000||$6.49||$97,350.00||535,865|| |
|5/13/2014||Anthony Sinskey||Director||Buy||5,000||$6.74||$33,700.00|| |
|5/8/2014||Michael Porter||Director||Buy||10,000||$6.59||$65,900.00||520,865|| |
|5/7/2014||Gary Crocker||Director||Buy||4,400||$6.77||$29,788.00|| |
|5/6/2014||Gary Crocker||Director||Buy||17,500||$6.89||$120,575.00||2,783,271|| |
|5/5/2014||Michael Porter||Director||Buy||15,000||$6.41||$96,150.00||485,865|| |
|5/5/2014||Robert Mulroy||CEO||Buy||5,000||$6.31||$31,550.00||946,069|| |
|12/17/2013||Michael Porter||Director||Buy||25,000||$4.75||$118,750.00||470,865|| |
|12/12/2013||William Mcclements||SVP||Buy||4,000||$4.26||$17,040.00||13,000|| |
|12/10/2013||Michael Porter||Director||Buy||18,000||$4.38||$78,840.00||445,865|| |
|12/6/2013||James Quigley||Director||Buy||39,000||$4.70||$183,300.00||51,500|| |
|12/4/2013||Robert Mulroy||CEO||Buy||33,100||$4.42||$146,302.00||989,644|| |
|12/3/2013||Sarah Nash||Director||Buy||47,500||$4.17||$198,075.00||976,994|| |
|12/2/2013||William Mcclements||SVP||Buy||2,000||$4.06||$8,120.00||9,000|| |
|11/29/2013||Anthony Sinskey||Director||Buy||3,800||$3.92||$14,896.00||392,543|| |
|11/27/2013||Gary Crocker||Director||Buy||207,000||$3.72||$770,040.00|| |
|12/14/2012||John Mendelsohn||Director||Buy||5,000||$6.63||$33,150.00|| |
|12/13/2012||Gary L Crocker||Director||Buy||36,500||$6.77||$247,105.00|| |
|12/10/2012||Michael E Porter||Director||Buy||10,000||$6.08||$60,800.00|| |
|9/14/2012||Gary L Crocker||Director||Buy||64,800||$8.33||$539,784.00|| |
|8/24/2012||James H Quigley||Director||Buy||12,500||$7.55||$94,375.00|| |
Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines
Merrimack Pharmaceuticals (NASDAQ:MACK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Merrimack Pharmaceuticals (NASDAQ:MACK) Income Statement, Balance Sheet and Cash Flow Statement
Merrimack Pharmaceuticals (NASDAQ MACK) Stock Chart for Thursday, April, 26, 2018